Merck & Co. (NYSE: MRK) this morning reported better-than-expected third-quarter earnings, but the loss of market exclusivity for its Singulair in the United States and the impact of foreign exchange took a toll on the company’s sales.
The New Jersey-based drug maker posted adjusted earnings per share (EPS) of $0.95 on revenues of $11.49 billion. In the same period a year ago, the company reported EPS of $0.94 on revenues of $12.02 billion. The quarter’s results also compare to the Thomson Reuters consensus estimates for EPS of $0.93 and $11.57 billion in revenues.
The gross margin rose to 64.0% from 63.8% in the third quarter of last year.
“Our strong global sales this quarter offset the impact of the SINGULAIR patent expiry in the U.S.,” said Kenneth C. Frazier, Merck’s chairman and chief executive. “With our robust pipeline, we remain on target to submit multiple new products for marketing approval between now and the end of 2013, including suvorexant for insomnia, odanacatib for osteoporosis and TREDAPTIVE for multiple lipid parameters.”
Merck now expects full-year 2012 EPS to fall in the range of $3.78 and $3.82 and for revenues to come in at or near 2011 levels, or $48.05 billion. The Thomson Reuters consensus estimates call for EPS of $3.81 and $47.14 billion in revenues.
Shares are inactive in premarket trading but closed yesterday at $46.30. The 52-week range is $33.08 to $48.00. The mean price target before this report was $48.50 per share.
Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.